Y Intercept Hong Kong Ltd Buys 3,923 Shares of Silence Therapeutics plc (NASDAQ:SLN)

Y Intercept Hong Kong Ltd boosted its stake in Silence Therapeutics plc (NASDAQ:SLN) by 22.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,078 shares of the company’s stock after purchasing an additional 3,923 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.07% of Silence Therapeutics worth $383,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in SLN. Values First Advisors Inc. bought a new position in Silence Therapeutics during the 3rd quarter worth approximately $56,000. Quarry LP bought a new position in shares of Silence Therapeutics during the second quarter worth $114,000. Marshall Wace LLP grew its holdings in shares of Silence Therapeutics by 7.3% in the 2nd quarter. Marshall Wace LLP now owns 149,397 shares of the company’s stock valued at $2,839,000 after buying an additional 10,206 shares during the period. Verition Fund Management LLC bought a new stake in shares of Silence Therapeutics in the 3rd quarter valued at $207,000. Finally, Custom Index Systems LLC acquired a new stake in Silence Therapeutics during the 2nd quarter worth $282,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Analyst Upgrades and Downgrades

SLN has been the subject of several recent analyst reports. William Blair restated an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Jefferies Financial Group assumed coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 target price on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 price target on shares of Silence Therapeutics in a report on Tuesday, October 8th. BMO Capital Markets restated an “outperform” rating on shares of Silence Therapeutics in a report on Monday, December 2nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Monday, December 9th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Stock Performance

SLN opened at $6.74 on Tuesday. The business’s 50-day simple moving average is $13.45 and its 200 day simple moving average is $16.97. Silence Therapeutics plc has a 52-week low of $5.81 and a 52-week high of $27.72. The firm has a market capitalization of $201.73 million, a PE ratio of -4.29 and a beta of 1.05.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.